Total Payments
$120,661
2024 Payments
$11,291
Companies
22
Transactions
84
Medicare Patients
2,073
Medicare Billing
$165,588
Payment Breakdown by Category
Research$57,488 (47.6%)
Consulting$54,799 (45.4%)
Food & Beverage$3,051 (2.5%)
Travel$2,764 (2.3%)
Other$2,540 (2.1%)
Education$19.17 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $57,488 | 14 | 47.6% |
| Consulting Fee | $54,799 | 19 | 45.4% |
| Food and Beverage | $3,051 | 36 | 2.5% |
| Travel and Lodging | $2,764 | 8 | 2.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,540 | 4 | 2.1% |
| Education | $19.17 | 3 | 0.0% |
Payments by Type
General
$63,173
70 transactions
Research
$57,488
14 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Genentech, Inc. | $38,700 | 4 | $0 (2019) |
| PFIZER INC. | $15,239 | 11 | $0 (2023) |
| Takeda Pharmaceuticals International, Inc. | $12,875 | 2 | $0 (2017) |
| Acorda Therapeutics, Inc | $10,106 | 8 | $0 (2019) |
| Ipsen Innovation | $9,600 | 2 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $7,808 | 7 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $7,497 | 10 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $5,402 | 5 | $0 (2017) |
| Novartis Pharmaceuticals Corporation | $3,978 | 3 | $0 (2018) |
| Eli Lilly and Company | $3,000 | 4 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $11,291 | 12 | Ipsen Innovation ($9,600) |
| 2023 | $5,309 | 7 | AstraZeneca Pharmaceuticals LP ($4,833) |
| 2022 | $1,734 | 7 | Eli Lilly and Company ($600.00) |
| 2021 | $8,753 | 7 | E.R. Squibb & Sons, L.L.C. ($2,703) |
| 2020 | $3,700 | 2 | PFIZER INC. ($3,200) |
| 2019 | $41,530 | 15 | Genentech, Inc. ($29,000) |
| 2018 | $18,230 | 21 | PFIZER INC. ($8,131) |
| 2017 | $30,114 | 13 | Takeda Pharmaceuticals International, Inc. ($12,875) |
All Payment Transactions
84 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/21/2024 | CVRx, Inc. | Barostim Neo System (Device) | Food and Beverage | Cash or cash equivalent | $92.19 | General |
| Category: Heart Failure and Hypertension | ||||||
| 10/17/2024 | CVRx, Inc. | Barostim Neo System (Device) | Food and Beverage | Cash or cash equivalent | $120.86 | General |
| Category: Heart Failure and Hypertension | ||||||
| 09/30/2024 | Boston Scientific Corporation | — | Food and Beverage | In-kind items and services | $101.40 | General |
| 09/24/2024 | Ipsen Innovation | — | — | Cash or cash equivalent | $1,200.00 | Research |
| Study: A Phase 2 Study to Assess the Efficacy and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva in Male and Female Paediatric and Adult Participants. | ||||||
| 08/08/2024 | Boston Scientific Corporation | BodyGuardian (Device) | Food and Beverage | In-kind items and services | $26.63 | General |
| Category: CDS - BG Mini Plus_RM | ||||||
| 07/11/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $134.71 | General |
| Category: Cardiovascular | ||||||
| 07/10/2024 | Ipsen Innovation | — | — | Cash or cash equivalent | $8,400.00 | Research |
| Study: A Phase 2 Study to Assess the Efficacy and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva in Male and Female Paediatric and Adult Participants. | ||||||
| 05/28/2024 | Boston Scientific Corporation | — | Food and Beverage | In-kind items and services | $18.70 | General |
| 05/07/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,074.00 | General |
| 04/08/2024 | Myocardial Solutions, Inc. | — | Food and Beverage | In-kind items and services | $100.49 | General |
| 03/11/2024 | Alnylam Pharmaceuticals Inc. | AMVUTTRA (Drug) | Food and Beverage | In-kind items and services | $13.45 | General |
| Category: Genetic Disease | ||||||
| 02/23/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Education | In-kind items and services | $9.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/30/2023 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $18.43 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/23/2023 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $42.53 | General |
| Category: Cardiovascular | ||||||
| 09/20/2023 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $3,490.50 | General |
| Category: Oncology | ||||||
| 07/10/2023 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $537.00 | General |
| 06/02/2023 | Alnylam Pharmaceuticals Inc. | AMVUTTRA (Drug) | Food and Beverage | In-kind items and services | $114.89 | General |
| Category: Genetic Disease | ||||||
| 02/16/2023 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $805.50 | General |
| 01/31/2023 | Eli Lilly and Company | — | — | In-kind items and services | $300.00 | Research |
| Study: A SINGLE-DOSE STUDY EVALUATING DIFFERENT DOSE LEVELS AND SUBCUTANEOUS INFUSION DURATIONS ON SAFETY PHARMACOKINETICS AND PHARMACODYNAMICS OF LY3461767 IN PARTICIPANTS WITH CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION | ||||||
| 11/08/2022 | Roche Diagnostics Corporation | — | Consulting Fee | Cash or cash equivalent | $390.00 | General |
| Category: None | ||||||
| 11/01/2022 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $21.03 | General |
| Category: Oncology | ||||||
| 08/23/2022 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $20.16 | General |
| Category: CARDIOVASCULAR | ||||||
| 05/12/2022 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $537.00 | General |
| 04/21/2022 | Boston Scientific Corporation | WATCHMAN Access System (Device) | Food and Beverage | In-kind items and services | $142.56 | General |
| Category: WATCHMAN_IC | ||||||
| 04/05/2022 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $23.12 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| T DM1 HIGH RISK EBC PTS WITH RESIDUAL INV DISEASE | Genentech, Inc. | $38,700 | 4 |
| A Phase 2 Study to Assess the Efficacy and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva in Male and Female Paediatric and Adult Participants. | Ipsen Innovation | $9,600 | 2 |
| TAFAMIDIS CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $5,800 | 3 |
| A SINGLE-DOSE STUDY EVALUATING DIFFERENT DOSE LEVELS AND SUBCUTANEOUS INFUSION DURATIONS ON SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF LY3461767 IN PARTICIPANTS WITH CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION | Eli Lilly and Company | $1,600 | 2 |
| Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials | Amgen Inc. | $388.27 | 1 |
| A SINGLE-DOSE STUDY EVALUATING DIFFERENT DOSE LEVELS AND SUBCUTANEOUS INFUSION DURATIONS ON SAFETY PHARMACOKINETICS AND PHARMACODYNAMICS OF LY3461767 IN PARTICIPANTS WITH CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION | Eli Lilly and Company | $300.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 641 | 718 | $123,317 | $29,111 |
| 2022 | 4 | 337 | 385 | $69,230 | $19,057 |
| 2021 | 9 | 418 | 590 | $163,925 | $45,841 |
| 2020 | 12 | 677 | 965 | $253,828 | $71,579 |
Total Patients
2,073
Total Services
2,658
Medicare Billing
$165,588
Procedure Codes
33
All Medicare Procedures & Services
33 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 111 | 150 | $46,050 | $9,693 | 21.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 79 | 79 | $25,517 | $7,641 | 29.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 44 | 44 | $26,268 | $5,866 | 22.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 23 | 23 | $9,568 | $2,446 | 25.6% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 294 | 316 | $8,216 | $1,921 | 23.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 23 | 24 | $4,992 | $1,213 | 24.3% |
| 93005 | Routine electrocardiogram (ecg) using at least 12 leads with tracing | Office | 2023 | 67 | 82 | $2,706 | $332.25 | 12.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 87 | 87 | $28,101 | $8,816 | 31.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 71 | 103 | $31,621 | $7,763 | 24.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 14 | 14 | $4,522 | $1,477 | 32.7% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2022 | 129 | 141 | $3,666 | $832.65 | 22.7% |
| 93005 | Routine electrocardiogram (ecg) using at least 12 leads with tracing | Office | 2022 | 36 | 40 | $1,320 | $169.25 | 12.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 136 | 158 | $37,048 | $14,553 | 39.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 34 | 107 | $30,629 | $8,800 | 28.7% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 50 | 50 | $24,766 | $8,349 | 33.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 36 | 36 | $21,601 | $5,611 | 26.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 42 | 67 | $13,662 | $3,810 | 27.9% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 24 | 24 | $10,635 | $2,616 | 24.6% |
| 94618 | Test for exercise-induced lung stress | Office | 2021 | 43 | 90 | $18,810 | $1,078 | 5.7% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 15 | 20 | $2,560 | $584.82 | 22.8% |
| 93000 | Routine ekg using at least 12 leads including interpretation and report | Office | 2021 | 38 | 38 | $4,214 | $441.18 | 10.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 151 | 189 | $43,092 | $15,069 | 35.0% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 86 | 86 | $41,452 | $13,455 | 32.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 85 | 194 | $40,557 | $11,197 | 27.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 56 | 131 | $38,639 | $11,043 | 28.6% |
About Dr. Daniel Lenihan, MD
Dr. Daniel Lenihan, MD is a Internal Medicine healthcare provider based in Cape Girardeau, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/28/2006. The National Provider Identifier (NPI) number assigned to this provider is 1780776799.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Daniel Lenihan, MD has received a total of $120,661 in payments from pharmaceutical and medical device companies, with $11,291 received in 2024. These payments were reported across 84 transactions from 22 companies. The most common payment nature is "" ($57,488).
As a Medicare-enrolled provider, Lenihan has provided services to 2,073 Medicare beneficiaries, totaling 2,658 services with total Medicare billing of $165,588. Data is available for 4 years (2020–2023), covering 33 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Cardiovascular Disease, Advanced Heart Failure and Transplant Cardiology
- Location Cape Girardeau, MO
- Active Since 09/28/2006
- Last Updated 06/19/2023
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1780776799
Products in Payments
- Herceptin (Biological) $38,700
- VYNDAQEL (Drug) $7,109
- XARELTO (Drug) $5,618
- SPRYCEL (Drug) $4,905
- KISQALI (Drug) $3,858
- CALQUENCE (Drug) $3,535
- NINLARO (Drug) $1,100
- Kyprolis (Biological) $388.27
- Barostim Neo System (Device) $213.05
- CAMZYOS (Drug) $177.24
- WATCHMAN Access System (Device) $142.56
- AMVUTTRA (Drug) $128.34
- ENTRESTO (Drug) $119.76
- Corlanor (Drug) $89.92
- INSPIRIS RESILIA aortic valve (Device) $54.17
- BodyGuardian (Device) $26.63
- HeartMate (Device) $18.17
- HeartMate 3 Left Ventricular Dev (Device) $18.17
- WAINUA (Drug) $9.00
- ELIQUIS (Drug) $3.20
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Cape Girardeau
Munis Raza, M.d, M.D
Internal Medicine — Payments: $15,330
Internal Medicine $15,330
Ira Taylor, Do, DO
Internal Medicine — Payments: $15,056
Internal Medicine $15,056
Dr. Chizor Iwuchukwu, M.d, M.D
Internal Medicine — Payments: $12,753
Internal Medicine $12,753
Dr. Steven Carr, Md, MD
Internal Medicine — Payments: $11,621
Internal Medicine $11,621
Nicholas Epstein
Internal Medicine — Payments: $3,732
Internal Medicine $3,732
Dr. Mark Mcnabb, D.o, D.O
Internal Medicine — Payments: $3,566
Internal Medicine $3,566